Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension
- PMID: 11882632
- DOI: 10.1161/hy0202.103788
Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension
Abstract
Epoxyeicosatrienoic acids (EETs) have antihypertensive properties and play a part in the maintenance of renal microvascular function. A novel approach to increase EET levels is to inhibit epoxide hydrolase enzymes that are responsible for conversion of biologically active EETs to dihydroxyeicosatrienoic acids (DHETs) that are void of effects on the preglomerular vasculature. We hypothesized that inhibition of soluble epoxide hydrolase (sEH) would lower blood pressure in angiotensin II (Ang II) hypertension. Rat renal cortical tissue was harvested and urine collected 2 weeks following implantation of an osmotic minipump containing Ang II (60 ng/min). Renal cortical sEH protein expression was significantly higher in Ang II hypertension compared with normotensive animals. Likewise, urinary 14,15-DHET levels were significantly increased in hypertensive compared with normotensive animals and averaged 8.1 +/- 1.3 and 2.7 +/- 1.1 ng/d; respectively. In additional experiments, the sEH inhibitor N-cyclohexyl-N-dodecyl urea (NCND; 3 mg/d) or vehicle (corn oil, 0.5 mL) was administered daily by intraperitoneal injection starting on day 10. Administration of NCND for 4 days lowered systolic blood pressure by 30 mm Hg in Ang II hypertensive animals, whereas the corn oil vehicle had no effect on blood pressure in normotensive or Ang II hypertensive animals. Measurement of blood pressure by indwelling arterial catheters in conscious animals with free movement in their cages confirmed that NCND had antihypertensive properties. Arterial blood pressure averaged 119 +/- 5 mm Hg in normotensive, 170 +/- 3 mm Hg in hypertensive and 149 +/- 10 mm Hg in NCND-treated, Ang II-infused animals. Administration of the potential metabolite of NCND, N-cyclohexylformamide to Ang II hypertensive rats did not lower the systolic blood pressure. These studies demonstrate that increased sEH expression in the Ang II hypertensive kidney leads to increased EET hydration. Moreover, sEH plays a role in the regulation of blood pressure, and inhibition of sEH during Ang II hypertension is antihypertensive.
Similar articles
-
Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.J Am Soc Nephrol. 2004 May;15(5):1244-53. J Am Soc Nephrol. 2004. PMID: 15100364
-
An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.Hypertension. 2005 Oct;46(4):975-81. doi: 10.1161/01.HYP.0000176237.74820.75. Epub 2005 Sep 12. Hypertension. 2005. PMID: 16157792 Free PMC article.
-
Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats.Basic Clin Pharmacol Toxicol. 2008 May;102(5):453-8. doi: 10.1111/j.1742-7843.2008.00213.x. Epub 2008 Feb 29. Basic Clin Pharmacol Toxicol. 2008. PMID: 18312493
-
Soluble epoxide hydrolase: a novel target for the treatment of hypertension.Recent Pat Cardiovasc Drug Discov. 2006 Jan;1(1):67-72. doi: 10.2174/157489006775244227. Recent Pat Cardiovasc Drug Discov. 2006. PMID: 18221075 Review.
-
Meloxicam fails to augment the reno-protective effects of soluble epoxide hydrolase inhibition in streptozotocin-induced diabetic rats via increased 20-HETE levels.Prostaglandins Other Lipid Mediat. 2017 Sep;132:3-11. doi: 10.1016/j.prostaglandins.2016.08.004. Epub 2016 Sep 3. Prostaglandins Other Lipid Mediat. 2017. PMID: 27596333 Review.
Cited by
-
The role of angiotensin II in regulating vascular structural and functional changes in hypertension.Curr Hypertens Rep. 2003 Apr;5(2):155-64. doi: 10.1007/s11906-003-0073-2. Curr Hypertens Rep. 2003. PMID: 12642016 Review.
-
Estrogen, aging and the cardiovascular system.Future Cardiol. 2009 Jan;5(1):93-103. doi: 10.2217/14796678.5.1.93. Future Cardiol. 2009. PMID: 19371207 Free PMC article. Review.
-
Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.Hypertension. 2020 Jul;76(1):3-15. doi: 10.1161/HYPERTENSIONAHA.120.13898. Epub 2020 Jun 1. Hypertension. 2020. PMID: 32475311 Free PMC article.
-
Multitarget molecule, PTUPB, to treat diabetic nephropathy in rats.Br J Pharmacol. 2021 Nov;178(22):4468-4484. doi: 10.1111/bph.15623. Epub 2021 Aug 12. Br J Pharmacol. 2021. PMID: 34255857 Free PMC article.
-
Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models.Eur J Pharm Sci. 2013 Mar 12;48(4-5):619-27. doi: 10.1016/j.ejps.2012.12.013. Epub 2013 Jan 3. Eur J Pharm Sci. 2013. PMID: 23291046 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous